One of the most senior figures in the City, Nikhil Rathi, welcomed the launch of HDFC’s masala bond.
Rathi, who is of Indian origin but born in the UK, is the CEO of the London Stock Exchange and also director of international development at the London Stock Exchange Group.
“It’s a fun job,” he told Eastern Eye, adding, “I am very proud of my heritage, very proud I am in this position to support the investment into India through the City of London.”
Alongside him at the event was another senior Indian-origin figure, Ramesh Chhabra, head of media relations at the London Stock Exchange. Known to friends as “Mesh”, he was until last year a special adviser to former chancellor George Osborne.
The London Stock Exchange dates back to 1801 and has the motto, Dictum Meum Pactum, which is Latin for, “Our word is our bond”.
“It’s the most international exchange in the world, the home for international investors, international issuers and today is a landmark event for Indian finance,” Rathi said, speaking immediately after the launch. “And we are very proud that London has been chosen as the partner of choice for the first corporate masala bond anywhere in the world, with HDFC being the pioneer in that market.”
“I believe there is a unique combination here of the India-UK financial partnership, with the deepest global financial centre here in London, the fastest=growing economy in the G20 in India and through the exchange I am very proud that we are able to bring that together,” he went on.
Asked whether the launch would strengthen UK-India relations, Rathi responded: “Absolutely. Prime minister Modi, in November last year, announced London as a masala bond centre – and that is very important because it indicates trust in the regulatory environment in London and trust by investors in London to support sustainable infrastructure financing in India – one of the most exciting and fastest-growing economies in the world.”
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.